Tvardi Therapeutics Reports Significant Q4/FY25 Losses, Short Cash Runway, and Mixed Clinical Trial Updates
TVRD is trading near its 52-week low of $3.05 (1.6% below the low).
Summary
Tvardi Therapeutics announced its Q4 and full-year 2025 financial results, reporting substantial net losses and a cash runway extending only into Q4 2026, alongside mixed updates on its clinical pipeline.
Key Events · Earnings and Guidance · TVRD
-
Substantial Net Losses Reported
The company reported a net loss of $18.2 million for the full year 2025 and $7.3 million for the fourth quarter of 2025.
-
Limited Cash Runway
Cash and cash equivalents, along with short-term investments, totaled $30.8 million as of December 31, 2025, with the company anticipating this will fund operations only into the fourth quarter of 2026.
-
Liver Cancer Trial Data Delayed
Topline data for the Phase 1b/2 REVERT LIVER CANCER trial (TTI-101) is now anticipated in the second half of 2026, a delay attributed to allowing for further data maturation and dose optimization.
-
Positive IPF Trial Analysis
Additional analysis from the REVERT IPF Phase 2 trial (TTI-101) demonstrated a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, and a 4.5-fold greater decline in IL-6.
Analysis · TVRD · Life Sciences
This 8-K details the company's severe financial position, confirming the concerns raised in the concurrently filed 10-K. The reported net loss of $18.2 million for the full year 2025 is substantial relative to the company's market capitalization. A cash runway projected only into the fourth quarter of 2026 indicates an urgent need for additional financing, which is particularly challenging for a company already facing a "going concern" warning. While the company provided positive additional analysis from its IPF trial and expressed optimism for its next-generation STAT3 inhibitor, the delay in topline data for the REVERT LIVER CANCER trial, despite being framed for data maturation, adds uncertainty. Investors should closely monitor the company's progress in securing additional capital and the upcoming clinical readouts, as the current financial situation poses significant risks.
At the time of this filing, TVRD was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.8M. The 52-week trading range was $3.05 to $43.65. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.